Affinage

HDAC7

Histone deacetylase 7 · UniProt Q8WUI4

Length
952 aa
Mass
102.9 kDa
Annotated
2026-06-10
100 papers in source corpus 49 papers cited in narrative 49 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

HDAC7 is a class IIa histone deacetylase that functions principally as a signal-responsive transcriptional corepressor, with its biological output dictated by phosphorylation-controlled nucleocytoplasmic shuttling and by non-catalytic scaffolding activities (PMID:11279209, PMID:15623513). Its catalytic domain adopts a class IIa-specific architecture with an enlarged active-site pocket and only low intrinsic deacetylase activity (PMID:18285338), and its robust nuclear enzymatic function depends on assembly with HDAC3 through the SMRT/N-CoR corepressors (PMID:11466315). HDAC7 represses transcription by binding MEF2 family factors (MEF2A/C/D) through its N-terminal repression domain in a manner independent of the catalytic domain (PMID:11279209), a module deployed across thymocyte selection where it silences Nur77 (PMID:12753745), B-lymphoid and myeloid lineage decisions (PMID:23696748, PMID:27810920), and Th17 and Treg programs (PMID:36516268, PMID:38657041). Activation signals relocalize HDAC7 out of the nucleus: PKD1, activated downstream of the TCR or VEGF receptor, phosphorylates conserved N-terminal serines (Ser155/Ser318/Ser448, or Ser178/Ser344/Ser479) to drive cytoplasmic export and derepression of target genes (PMID:15623513, PMID:18617643), while opposing phosphatases (PP1β/MYPT1, PP2A-Bα) and the ROCK pathway restore nuclear localization and repression (PMID:17369396, PMID:23955003). Beyond MEF2 corepression, HDAC7 deacetylates an expanding set of non-histone substrates—STAT3 (PMID:29126425), β-catenin at Lys49 (PMID:35277183, PMID:30691485), HSP70 at K246 (PMID:25173798), FOXP1 (PMID:37507770), TFEB at K310 (PMID:39806423), PINK1 (PMID:41286926), and ENO1 (PMID:40536557)—thereby controlling tumor signaling, lysosomal biogenesis, mitophagy, and stem-cell senescence. It also acts as a deacetylase-independent scaffold, engaging the TRAF6-TAK1 complex and IKKα/β to drive MAPK/NF-κB inflammatory signaling (PMID:35871708, PMID:39049738), and in macrophages serves as a bifunctional immunometabolic switch coupling TLR4 signals to enzyme-independent glycolytic reprogramming and enzyme-dependent inflammatory cytokine and pentose-phosphate-pathway responses (PMID:36649417, PMID:34811804). HDAC7 protein abundance is set by competing ubiquitin and SUMO machinery: USP10 stabilizes it by deubiquitination (PMID:35277183), CBX4 and FBXW7 promote its degradation (PMID:28283560), SIK1 phosphorylates and stabilizes cytoplasmic HDAC7 to drive cardiac hypertrophy (PMID:32106109), and TRIM28-mediated sumoylation elevates its levels (PMID:39629136).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2001 High

    Established the founding mechanism of HDAC7 as a MEF2 corepressor and revealed that its repressive output is structurally separable from its catalytic domain.

    Evidence GST pulldown, Co-IP, reporter assays and domain mapping in mammalian cells

    PMID:11279209 PMID:11466315

    Open questions at the time
    • Did not resolve how nuclear export is triggered physiologically
    • In vitro deacetylase activity of HDAC7 itself not quantified
  2. 2003 High

    Placed HDAC7-MEF2 repression in a physiological circuit by showing it gates Nur77-dependent thymocyte apoptosis, with nuclear export as the regulatory event.

    Evidence Reporter assays, triple-serine mutant, RNAi and thymocyte apoptosis assays

    PMID:12753745

    Open questions at the time
    • Kinase responsible for the export-driving phosphorylation not identified
    • Opposing phosphatase unknown
  3. 2004 High

    Identified PKD1 as the TCR-activated kinase that phosphorylates HDAC7 N-terminal serines to drive nuclear export, defining the signal-to-localization link.

    Evidence In vitro kinase assay, site-directed mutagenesis, dominant-negative PKD1, microscopy

    PMID:15623513

    Open questions at the time
    • Did not identify the export receptor/14-3-3 machinery
    • Reversal mechanism not addressed
  4. 2007 High

    Closed the regulatory loop by identifying PP1β/MYPT1 as the phosphatase that dephosphorylates HDAC7 to restore nuclear repression, with ROCK upstream.

    Evidence Co-IP, phosphatase assays, siRNA and thymocyte apoptosis readouts

    PMID:17369396

    Open questions at the time
    • Direct versus indirect dephosphorylation not fully dissected
    • Other phosphatases not excluded
  5. 2008 High

    Defined the class IIa-specific active-site architecture and confirmed low but genuine intrinsic deacetylase activity, explaining why HDAC7 relies on partner enzymes.

    Evidence X-ray crystallography of the catalytic domain with inhibitor complexes plus in vitro activity assay

    PMID:18285338

    Open questions at the time
    • Physiological substrate of the isolated catalytic domain not defined
    • Full-length and complex-bound structures not solved
  6. 2008 High

    Generalized the PKD1-HDAC7 shuttling module beyond immunity to VEGF-driven angiogenic gene expression in endothelial cells.

    Evidence PLCγ/PKC/PKD1 pathway dissection, phosphomutants, dominant-negatives, tube formation and sprouting assays

    PMID:18617643

    Open questions at the time
    • Direct transcriptional targets at MT1-MMP/MMP10 loci not mapped by ChIP
    • Role of catalytic activity not isolated
  7. 2013 High

    Extended MEF2 corepression to lineage commitment, showing HDAC7-MEF2C represses myeloid genes to enforce B-lymphoid identity.

    Evidence Co-IP, ChIP, microarray and functional transdifferentiation assays in pre-B cells

    PMID:23696748

    Open questions at the time
    • Catalytic dependence of repression not resolved
    • Recruitment to specific enhancers versus promoters not separated
  8. 2016 High

    Demonstrated in vivo that HDAC7-MEF2C occupancy enforces early B cell development and prevents lineage promiscuity, linking loss to altered active histone marks.

    Evidence Conditional knockout mouse, ChIP-seq, Co-IP and flow cytometry

    PMID:27810920

    Open questions at the time
    • Mechanism connecting HDAC7 loss to gain of active marks not biochemically defined
    • Catalytic requirement not tested in vivo
  9. 2017 Medium

    Identified non-histone substrate deacetylation as a distinct HDAC7 mechanism by showing it directly deacetylates STAT3 to restrain its activation in lung tumors.

    Evidence Co-IP, pulldown, deacetylation assay, Hdac7+/-/K-Ras mouse model with dominant-negative STAT3 rescue

    PMID:29126425

    Open questions at the time
    • Acetyl-lysine site on STAT3 not mapped
    • Direct enzyme-substrate kinetics not established
  10. 2020 High

    Revealed a cytoplasmic, MEF2-independent role: SIK1 phosphorylates and stabilizes HDAC7 as a prohypertrophic effector driving cardiomyocyte remodeling.

    Evidence Gain/loss-of-function in rodents and hiPSC-cardiomyocytes, kinase assay, Co-IP

    PMID:32106109

    Open questions at the time
    • Cytoplasmic effector mechanism (substrate or scaffold) not fully defined
    • Phosphosite mediating stabilization not specified here
  11. 2022 Medium

    Connected HDAC7 to Wnt signaling and its own stability control, showing it deacetylates β-catenin at Lys49 to promote nuclear translocation while USP10 stabilizes HDAC7.

    Evidence Co-IP, deacetylation/phosphorylation readouts, lentiviral knockdown and xenograft

    PMID:30691485 PMID:35277183

    Open questions at the time
    • Direct versus indirect effect on β-catenin Ser45 phosphorylation not resolved
    • Reciprocal deubiquitination kinetics not quantified
  12. 2022 Medium

    Defined deacetylase-independent scaffolding of NF-κB signaling, with HDAC7 deacetylating and activating IKKα/β to drive astrocyte inflammation.

    Evidence Co-IP, AAV overexpression, siRNA, pharmacological inhibition and behavioral assays

    PMID:35871708

    Open questions at the time
    • IKK acetyl-lysine sites not mapped
    • Distinction between scaffold and catalytic contribution incomplete
  13. 2023 High

    Resolved HDAC7 as a bifunctional immunometabolic switch in macrophages, separating enzyme-independent glycolytic reprogramming from enzyme-dependent inflammatory and antimicrobial outputs.

    Evidence Hdac7-deficient macrophages with enzyme-dead reconstitution, ECAR, metabolomics, cytokine and bacterial killing assays

    PMID:34811804 PMID:36649417

    Open questions at the time
    • Molecular target of the enzyme-independent glycolytic function not identified
    • Direct metabolic-enzyme substrates of HDAC7 not defined
  14. 2024 Medium

    Identified the TRAF6-TAK1 complex as a direct deacetylase-independent partner coupling HDAC7 to TLR4-driven MAPK/NF-κB cytokine production, validated by selective PROTAC degradation.

    Evidence PROTAC degrader B4, Co-IP, cytokine assays and mouse LPS model

    PMID:39049738

    Open questions at the time
    • Stoichiometry and binding interface with TRAF6-TAK1 not defined
    • Single lab, no reciprocal structural validation
  15. 2025 Medium

    Expanded the non-histone substrate repertoire into proteostasis and organelle quality control, with HDAC7 deacetylating TFEB (K310), PINK1 and ENO1 to suppress lysosomal biogenesis, mitophagy and metabolism.

    Evidence Co-IP, mass spectrometry, site mutagenesis, AAV genetic models and pharmacological inhibition

    PMID:39806423 PMID:40536557 PMID:41286926

    Open questions at the time
    • Direct enzymatic specificity versus complex-dependent activity not separated for each substrate
    • In vitro reconstitution of deacetylation reactions not shown

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how a single low-activity catalytic domain achieves the broad non-histone substrate selectivity observed, and which substrates require complex-assembled versus intrinsic HDAC7 activity.
  • No structure of HDAC7 bound to a non-histone substrate
  • Substrate-recognition determinants undefined
  • Quantitative contribution of HDAC3-complex activity to each reported substrate unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 8 GO:0140110 transcription regulator activity 6 GO:0060090 molecular adaptor activity 2 GO:0042393 histone binding 1
Localization
GO:0005829 cytosol 5 GO:0005634 nucleus 4 GO:0005739 mitochondrion 1
Pathway
R-HSA-168256 Immune System 5 R-HSA-162582 Signal Transduction 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-4839726 Chromatin organization 3 R-HSA-1430728 Metabolism 2
Partners
CTNNB1HDAC3IKBKBMEF2CMYPT1PKD1STAT3TRAF6
Complex memberships
SMRT/N-CoR-HDAC3 corepressor complex

Evidence

Reading pass · 49 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2008 Crystal structures of human HDAC7 catalytic domain (cdHDAC7) and its complexes with two hydroxamate inhibitors revealed a class IIa-specific zinc binding motif adjacent to the active site, an enlarged active site pocket with different topology compared to class I/IIb HDACs, and a low but measurable intrinsic deacetylase activity inhibitable by known HDAC inhibitors. X-ray crystallography; in vitro deacetylase activity assay; inhibitor binding studies The Journal of biological chemistry High 18285338
2001 HDAC7 deacetylase activity in the cell nucleus depends on its interaction with the class I HDAC3; cytoplasmic HDAC7 not bound to HDAC3 is enzymatically inactive. The corepressors SMRT and N-CoR serve as mediators by binding class II HDACs and HDAC3 via two distinct repressor domains. Co-immunoprecipitation; fractionation; functional deacetylase assays; domain mapping The Journal of biological chemistry High 11466315
2001 HDAC7 directly interacts with MEF2 proteins (MEF2-A, -C, -D) via its N-terminal 121 amino acids (repression domain 1), and the MADS domain of MEF2 mediates this interaction; HDAC7-mediated MEF2 repression is independent of the C-terminal deacetylase domain. HDAC7 also interacts with CtBP and other class I/II HDACs. During myogenesis induced by serum withdrawal, HDAC7 translocates from nucleus to cytoplasm. GST pulldown; co-immunoprecipitation; reporter assays; domain-deletion mapping; fluorescence microscopy The Journal of biological chemistry High 11279209
2003 HDAC7 represses Nur77 transcription via MEF2D in CD4+CD8+ double-positive thymocytes. TCR activation triggers nuclear export of HDAC7, leading to Nur77 derepression and apoptosis. A triple serine mutant (S155A/S318A/S448A) of HDAC7 is not exported and suppresses TCR-mediated apoptosis; RNAi knockdown of HDAC7 increases TCR-mediated apoptosis. Reporter assays; site-directed mutagenesis; RNAi; fluorescence microscopy; thymocyte apoptosis assays Immunity High 12753745
2004 Protein kinase D1 (PKD1) is activated after TCR engagement, physically interacts with HDAC7, and phosphorylates three serines (Ser155, Ser318, Ser448) at its N-terminus, causing nuclear export of HDAC7 via a calcium-independent pathway. Kinase-inactive PKD1 blocked HDAC7 shuttling. PKD1 activation leads to Nur77 transcriptional activation via MEF2 binding sites. Co-immunoprecipitation; in vitro kinase assay; site-directed mutagenesis; dominant-negative PKD1; fluorescence microscopy; reporter assays The Journal of biological chemistry High 15623513
2007 Protein phosphatase 1β (PP1β) and myosin phosphatase targeting subunit 1 (MYPT1) associate with HDAC7 in thymocytes and dephosphorylate HDAC7, promoting its nuclear localization and repression of Nur77, thereby inhibiting apoptosis in CD4+CD8+ thymocytes. ROCK signaling pathway operates upstream via MYPT1. Co-immunoprecipitation; phosphatase assays; siRNA knockdown; fluorescence microscopy; apoptosis assays Genes & development High 17369396
2004 HDAC7 localizes to the mitochondrial inner membrane space of prostate epithelial cells and undergoes cytoplasmic relocalization upon initiation of apoptosis. Subcellular fractionation; immunofluorescence microscopy; mitochondrial isolation The Journal of biological chemistry Medium 15364908
2001 HDAC7 interacts with the endothelin receptor A (ETA) as determined by yeast two-hybrid, GST pulldown, and co-immunoprecipitation. ET-1 stimulation causes internalization of ETA to a perinuclear compartment and simultaneous nuclear export of HDAC7 to the same compartment. Yeast two-hybrid; GST pulldown; co-immunoprecipitation; fluorescence microscopy The Journal of biological chemistry Medium 11262386
2008 VEGF stimulates PKD1-dependent phosphorylation of HDAC7 at Ser178, Ser344, and Ser479 via a PLCγ/PKC/PKD1 pathway, causing cytoplasmic accumulation of HDAC7. A phosphorylation-deficient HDAC7 mutant inhibited VEGF-induced expression of MT1-MMP and MMP10 and suppressed endothelial cell migration, tube formation, and microvessel sprouting. Pharmacological inhibitors; siRNA; dominant-negative adenoviruses; western blotting; tube formation/migration assays; phosphomutant constructs Arteriosclerosis, thrombosis, and vascular biology High 18617643
2010 HDAC7 protects neurons from apoptosis by directly associating with the c-jun gene promoter and inhibiting c-jun transcription. This neuroprotection is independent of HDAC7's catalytic domain and cannot be blocked by chemical HDAC inhibitors. shRNA knockdown; forced expression; chromatin immunoprecipitation (ChIP); catalytic domain mutants; neuronal apoptosis assay The Journal of biological chemistry Medium 21118817
2011 HDAC7 interacts with the transcription factor Mitf in RAW 264 osteoclast precursor cells and represses Mitf transcriptional activity; either the amino- or carboxyl-terminus of HDAC7 is sufficient for this repression. Knockdown of HDAC7 accelerates osteoclast differentiation, and the repression is insensitive to trichostatin A, indicating a deacetylation-independent mechanism. Co-immunoprecipitation; siRNA knockdown; reporter assays; domain-deletion analysis; osteoclast differentiation assay The Journal of biological chemistry Medium 21324898
2009 HDAC7 undergoes alternative splicing during ES cell differentiation toward smooth muscle cells (SMCs); the spliced form modulates the SRF-myocardin complex to promote SMC differentiation. PDGF enhanced this splicing and SMC differentiation. Western blot; immunofluorescence; overexpression in ES cells; SM22-LacZ transgenic embryonic cell culture; co-immunoprecipitation of SRF-myocardin complex Journal of cell science Medium 19174469
2010 Sp1 binds the HDAC7 promoter at a minimal PDGF-BB-responsive element (−343 to −292 bp) containing a Sp1 site, activating HDAC7 transcription during SMC differentiation. Mutation of the Sp1 site abolishes PDGF-BB-induced HDAC7 promoter activity, and Sp1 knockdown abrogates PDGF-BB-induced HDAC7 upregulation and SMC gene expression. Promoter deletion analysis; luciferase reporter assay; site-directed mutagenesis; ChIP; siRNA knockdown; overexpression The Journal of biological chemistry Medium 20889501
2013 In pre-B cells, HDAC7 interacts with transcription factor MEF2C and is recruited to MEF2 binding sites at promoters of macrophage-specific genes to repress them. Re-expression of HDAC7 during pre-B to macrophage transdifferentiation blocks induction of myeloid genes and suppresses phagocytosis and cytokine responses. Co-immunoprecipitation; chromatin immunoprecipitation (ChIP); microarray; overexpression/knockdown; phagocytosis and cytokine assays PLoS genetics High 23696748
2012 HDAC7 binds β-catenin in proliferating chondrocytes and suppresses β-catenin transcriptional activity and cyclin D1 expression. Stimulation of chondrocyte maturation causes HDAC7 translocation to the cytoplasm where it is degraded by the proteasome, releasing β-catenin to the nucleus. Postnatal conditional Hdac7 deletion in chondrocytes expands the proliferative zone. Co-immunoprecipitation; conditional knockout (tamoxifen-inducible Cre); adenoviral Cre deletion; nuclear/cytoplasmic fractionation; reporter assays; histology The Journal of biological chemistry High 25389289
2012 HDAC7 overexpression suppresses and HDAC7 deletion enhances osteoclastogenesis. Mechanistically, HDAC7 attenuates β-catenin function and cyclin D1 expression to reduce precursor proliferation; upon RANKL signaling, HDAC7 suppresses NFATc1 and prevents β-catenin downregulation to block differentiation. Conditional HDAC7 knockout in osteoclast lineage reduces bone mass due to elevated bone resorption. Conditional knockout mice; bone marrow differentiation assays; overexpression; western blot; reporter assay Molecular endocrinology High 23204328
2013 PP2A-Bα phosphatase controls HDAC7 activity; loss of PP2A-Bα abrogates HDAC7 transcriptional repression, leading to increased ArgBP2 expression, RhoA hyperactivation, and disruption of endothelial cytoskeletal dynamics and vascular lumen formation. This PP2A-Bα/HDAC7/ArgBP2 axis maintains vascular lumens. siRNA knockdown; zebrafish morpholino; reporter assays; western blot; RhoA activity assay; tubulogenesis assays The EMBO journal Medium 23955003
2012 HDAC7 silencing in HUVECs results in H3 histone acetylation at the AKAP12 promoter, increasing AKAP12 mRNA/protein levels; elevated AKAP12 mediates PKC-dependent STAT3 phosphorylation. AKAP12 upregulation following HDAC7 knockdown is responsible for inhibition of endothelial migration and tube formation. siRNA; proteomics; ChIP; western blot; migration and tube formation assays Angiogenesis Medium 22584896
2014 Deacetylation of HSP70 at K246 by HDAC1 and HDAC7 promotes cancer cell survival and therapy resistance by inhibiting autophagic cell death. miR-34a targets HDAC1 and HDAC7 to suppress this deacetylation. miRNA target validation (luciferase); site-directed mutagenesis of HSP70 K246; co-immunoprecipitation; western blot; cell survival and autophagy assays Cancer letters Medium 25173798
2017 HDAC7 directly interacts with and deacetylates STAT3, reducing STAT3 acetylation and tyrosine phosphorylation. Loss of HDAC7 in mouse lung tumors or human cancer cell lines results in enhanced STAT3 acetylation/activation. The tumor-promoting effect of Hdac7 in K-Ras mice was reversed by dominant-negative Stat3. Co-immunoprecipitation; pulldown assay; western blot; in vivo mouse model (Hdac7+/-/K-Ras); dominant-negative rescue; deacetylation assay Molecular cancer Medium 29126425
2022 HDAC7 deacetylates β-catenin at Lys49, reducing its phosphorylation at Ser45, which promotes β-catenin nuclear translocation and TCF4-dependent activation of FGF18. Deubiquitinase USP10 interacts with HDAC7 and stabilizes it by preventing its ubiquitin-proteasome degradation. Co-immunoprecipitation; western blot; lentiviral overexpression/knockdown; in vivo xenograft; luciferase reporter Journal of experimental & clinical cancer research : CR Medium 35277183
2019 ZNF326 activates HDAC7 transcription by binding to the HDAC7 promoter via its zinc-finger and transcriptional activation domains. Upregulated HDAC7 then deacetylates β-catenin at Lys49, decreasing its phosphorylation at Ser45, promoting β-catenin nuclear import and TCF4 binding to activate Wnt target genes. ChIP; dual-luciferase assay; GST pulldown; co-immunoprecipitation; western blot; site-directed mutagenesis Journal of experimental & clinical cancer research : CR Medium 30691485
2015 Ectopically expressed HDAC7 in leukemia/lymphoma cells localizes to the nucleus, interacts with MEF2C, HDAC3, and SMRT to downregulate c-Myc and induce apoptosis. Both the MEF2C-interaction domain and the catalytic domain of HDAC7 are required for reduced cell viability. Co-immunoprecipitation; overexpression; xenograft model; reporter assay; domain-deletion analysis Cell death & disease Medium 25675295
2016 In B cell progenitors, HDAC7 interacts with MEF2C and is recruited to promoters and enhancers of myeloid and T-lymphocyte genes; conditional HDAC7 knockout blocks early B cell development, causes lymphopenia, and leads to pro-B cell lineage promiscuity. HDAC7 absence leads to increased enrichment of active histone marks at target gene loci. Conditional knockout mouse model; ChIP-seq; co-immunoprecipitation; flow cytometry; gene expression analysis The Journal of experimental medicine High 27810920
2017 Tonic LAT-mediated TCR signals constitutively export HDAC7 from the nucleus of naive CD4+ T cells, maintaining expression of HDAC7 target genes Nur77 and Irf4. Without tonic LAT signals, HDAC7 is nuclear, repressing Nur77 and Irf4. Genetic (LAT-deficient mice); nuclear export assays; gene expression profiling; functional T cell assays Cell reports Medium 28538176
2020 SIK1 phosphorylates and stabilizes HDAC7 protein during cardiac stress; this HDAC7 stabilization is required for pathologic cardiomyocyte remodeling and c-Myc induction. HDAC7 acts as a prohypertrophic effector in the cytoplasm of cardiomyocytes, representing a functional departure from canonical nuclear MEF2 corepressor activity. Gain- and loss-of-function in rodent models and hiPSC-derived cardiomyocytes; western blot; co-immunoprecipitation; kinase assay The Journal of clinical investigation High 32106109
2010 Nuclear-retained HDAC7 mutants inhibit C2C12 myocyte differentiation and reduce MHC and myogenin expression; this inhibition is partially relieved by a mutation disrupting HDAC7-MEF2 interaction. Phosphorylated HDAC7 (pS178) colocalizes with actin filaments in myocytes, and nuclear-retained HDAC7 causes defects in myocyte migration. Stable expression of HDAC7 mutants; immunofluorescence; phalloidin staining; differentiation and migration assays; site-directed mutagenesis Biochimica et biophysica acta Medium 20621129
2006 HDAC7 acts as a corepressor of androgen receptor (AR); in absence of AR ligand, HDAC7 is cytoplasmic, but androgen-occupied AR induces nuclear transfer of HDAC7. The deacetylase activity of HDAC7 is partly dispensable for AR repression, and PML-3 overexpression sequesters HDAC7 to PML-3 domains to relieve HDAC7-mediated AR repression. Fluorescence microscopy; co-immunoprecipitation; reporter assays; domain mutagenesis; PML-3 overexpression Experimental cell research Medium 16860317
2017 HDAC7 is ubiquitinated by the E3 ligase CBX4 in hippocampal neurons after contextual fear conditioning (CFC) training, leading to HDAC7 ubiquitin-dependent degradation. Decreased HDAC7 levels correlate with increased Nur77 expression, which modulates CFC memory formation. Immunoprecipitation; western blot; hippocampal injection of siRNA; fear conditioning behavioral assay; ubiquitination assay The Journal of neuroscience Medium 28283560
2022 HDAC7 interacts with IKKα and IKKβ to promote their deacetylation and activation, leading to NF-κB activation in astrocytes. Astrocyte-specific HDAC7 overexpression induces NF-κB-driven pro-inflammatory gene expression and anxiety-like behaviors in mice. Co-immunoprecipitation; western blot; AAV-mediated overexpression; siRNA knockdown; pharmacological inhibition; behavioral assays Molecular neurobiology Medium 35871708
2024 Using a selective PROTAC degrader (B4), HDAC7 was shown to have a deacetylase-independent proinflammatory role in macrophages; HDAC7 directly interacts with the TRAF6-TAK1 complex, activating MAPK/NF-κB signaling downstream of TLR4 and driving production of specific proinflammatory cytokines. PROTAC-mediated targeted degradation; co-immunoprecipitation; western blot; cytokine assays; mouse LPS model Advanced science Medium 39049738
2023 In macrophages, HDAC7 functions as a metabolic switch: LPS (distal danger) triggers HDAC7-dependent glycolysis and IL-1β production, while bacterial challenge (proximal danger) induces HDAC7-mediated pentose phosphate pathway engagement via 6PGD, generating NADPH/ROS for antimicrobial killing and D-ribulose-5-phosphate (RL5P) with antimicrobial and immunomodulatory activities. Hdac7 enzymatic activity is required for IL-1β production but acts enzyme-independently for metabolic reprogramming. Hdac7-deficient macrophages; enzyme-dead mutant reconstitution; extracellular acidification rate (ECAR) assay; cytokine assays; metabolomics; UPEC killing assays Proceedings of the National Academy of Sciences High 36649417
2021 TLR4/LPS-activated HDAC7 enzymatic activity in macrophages is required for production of specific inflammatory mediators (IL-1β, CCL2), while its metabolic glycolysis-reprogramming function is enzyme-independent. TLR-inducible class IIa HDAC activity is absent in Hdac7-deficient macrophages and requires MyD88 (except for TLR3 agonist). Hdac7-deficient mouse macrophages; enzyme-dead mutant reconstitution; ECAR assay; cytokine assays; MyD88-deficient cells Journal of leukocyte biology Medium 34811804
2021 TGF-β signaling, in concert with HDAC7, suppresses expression of TCA cycle enzymes in renal cell carcinoma (RCC) by repressing PGC-1α. Pharmacologic inhibition of TGF-β restores TCA cycle enzyme expression and suppresses tumor growth in an orthotopic RCC model. Proteomics; gene expression analysis; PGC-1α overexpression; TGF-β inhibition in orthotopic model; metabolic flux analysis JCI insight Medium 34609963
2022 HDAC4, -5, and -7 dissociate from corepressor NCoR in the presence of acetyllysine-containing peptides (consistent with reader function). Mutation of a critical AR acetylation site regulated AR transcriptional activation through an HDAC7-NCoR-HDAC3 dissociation mechanism, providing evidence that HDAC7 can function as an epigenetic acetyllysine reader. NCoR dissociation assay with acetyllysine peptides; AR mutagenesis; reporter assay; co-immunoprecipitation Cell chemical biology Medium 35709754
2022 In Tregs, wild-type HDAC7 regulates genes essential for Foxp3+ Treg function. Treg-specific conditional hemizygous deletion of HDAC7 increases EAE severity. The MS-protective HDAC7 R166H (R150H in mouse) variant confers enhanced Treg suppressive capacity in vitro and decreases EAE severity in vivo via transcriptomic alterations in brain-infiltrating Tregs. Treg-specific conditional knockout; knock-in mouse model; EAE model; in vitro Treg suppression assay; single-cell RNA-seq; transcriptomic analyses Science translational medicine High 36516268
2024 In Th17 cell differentiation, HDAC7 collaborates with transcription factor Aiolos and Smrt/Ncor1-Hdac3 corepressors to repress transcription of Th17 negative regulators (including Il2). Hdac7 is dispensable in other Th subtypes. Genetic or pharmacological inhibition of Hdac4/7 mitigates Th17-mediated intestinal inflammation in a colitis model. Conditional knockout (Hdac7 and Hdac4 in T cells); co-immunoprecipitation; ChIP; colitis mouse model; cytokine assays Proceedings of the National Academy of Sciences High 38657041
2022 HDAC7 deficiency in pro-B cells induces TET2 expression, promoting DNA 5-hydroxymethylation and global chromatin de-condensation. HDAC7 loss also results in aberrant expression of microRNAs and LINE-1 transposable elements, revealing an HDAC7-TET2 epigenetic axis essential for early B cell development. Conditional knockout; 5-hmC profiling; histone mark analysis; microRNA/LINE-1 expression; chromatin conformation analysis Nucleic acids research Medium 35904805
2019 In breast cancer stem-like cells, HDAC7 binds near transcription start sites and super-enhancers of oncogenes (c-MYC, CD44, etc.) and contributes to H3K27ac levels and transcriptional activation at these loci. HDAC1 or HDAC3 inhibition/knockdown leads to HDAC7 downregulation associated with decreased H3K27ac at super-enhancers. ChIP-seq; siRNA knockdown; western blot; gene expression analysis in CSC vs. non-CSC models Oncogene Medium 31375747
2010 HDAC7 silencing in cancer cells causes G1/S arrest by suppressing c-Myc expression and increasing p21/p27. HDAC7 directly binds the c-Myc gene promoter, and its silencing decreases histone H3/H4 acetylation and RNA polymerase II occupancy at the c-Myc locus. Ectopic c-Myc expression reverses G1/S arrest and cellular senescence induced by HDAC7 knockdown. siRNA knockdown; ChIP; cell cycle analysis; overexpression rescue; western blot Journal of molecular medicine Medium 21120446
2023 HDAC7 deacetylates FOXP1 in mesenchymal stem cells (MSCs); FOXP1 and HDAC7 cooperatively sustain MSC self-renewal and attenuate cellular senescence. Mutation of the FOXP1 acetylation site T172G (homologous to human T176G) profoundly augments MSC expansion capacity. Mass spectrometry; single and double knockout mice; site-directed mutagenesis (T176G); hESC-derived MSC overexpression; proliferation/senescence assays Stem cell research & therapy Medium 37507770
2025 HDAC7 deacetylates TFEB at K310 in astrocytes, preventing TFEB nuclear translocation and reducing lysosomal biogenesis and tau clearance. Genetic or pharmacological inhibition of HDAC7 restores TFEB acetylation, enhances lysosomal biogenesis, and improves tau clearance and cognitive function in PS19 mice. Co-immunoprecipitation; mass spectrometry; immunoprecipitation; luciferase reporter; AAV-shRNA in PS19 mice; tau uptake/degradation assays; pharmacological inhibition (TMP195) Molecular neurodegeneration High 39806423
2025 HDAC7 deacetylates PINK1, suppressing phosphorylation of Parkin at Ser65 and inhibiting TOMM20/40 recruitment, thereby impairing PINK1-Parkin-dependent mitophagy in astrocytes. Astrocyte-specific HDAC7 knockout or pharmacological inhibition restores mitophagy, ATP release, and reverses depressive-like behaviors in mice. Co-immunoprecipitation; mass spectrometry; western blot; AAV-mediated astrocyte-specific KO; pharmacological inhibition; mitophagy assays; behavioral assays Journal of neuroinflammation Medium 41286926
2013 HDAC7 interacts with HDAC1, HDAC2, and HDAC7 (itself) via pulldown and co-immunoprecipitation, mediating transcriptional repression by Holocarboxylase synthetase (HCS) in a deacetylase/biotin-independent manner. In vitro pulldown; co-immunoprecipitation; GAL4-luciferase reporter assay Molecular genetics and metabolism Low 24239178
2025 HDAC7 promotes β-catenin deacetylation, phosphorylation modulation, and nuclear translocation in SCLC cells, forming a β-catenin/TCF/LEF1 complex that activates c-Myc and XPO1 transcription. This HDAC7/β-catenin/c-Myc/XPO1 axis drives SCLC proliferation. RNA sequencing; western blot; co-immunoprecipitation; xenograft and organoid models; ChIP Advanced science Medium 39887933
2024 TRIM28-mediated sumoylation of HDAC7 upregulates its protein levels; sumoylated HDAC7 mediates H3K27 deacetylation to inhibit SOX8, which facilitates JUN-dependent LGALS3 transcription to promote GBM mesenchymal transition and macrophage M2 polarization. Mass spectrum; RNA immunoprecipitation; co-immunoprecipitation; ChIP; gain/loss-of-function assays in vitro and in vivo Theranostics Medium 39629136
2024 FBXW7 interacts with HDAC7 via immunoprecipitation and promotes HDAC7 ubiquitination in glioblastoma cells; HDAC7 overexpression blocks FBXW7-induced apoptosis. Co-immunoprecipitation; ubiquitination assay; overexpression rescue; western blot Cell biology international Low 34288252
2025 HDAC7 reduces the acetylation level of Enolase 1 (ENO1), thereby enhancing malignant proliferation of ARID1A-deficient HCC cells. The transcription factor PU.1 (induced by ARID1A loss) drives HDAC7 transcription. Targeting HDAC7 inhibited ARID1A-deficient tumor xenograft growth. RNA-seq; ChIP; luciferase reporter; protein IP + mass spectrometry (identifying ENO1 as substrate); xenograft; western blot Hepatology communications Medium 40536557
2014 ROCK signaling via MYPT1 (myosin phosphatase) controls nucleocytoplasmic shuttling of HDAC7; inhibition of the ROCK pathway in iPSCs leads to nuclear export of HDAC7 and transcriptional activation of the orphan nuclear receptor NR4A1. iPSC model; ROCK inhibition; immunofluorescence microscopy; reporter assay Biochemical and biophysical research communications Low 25511694

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. The Journal of biological chemistry 226 18285338
2001 Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. The Journal of biological chemistry 193 11466315
2003 HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 190 12753745
2001 A dynamic role for HDAC7 in MEF2-mediated muscle differentiation. The Journal of biological chemistry 176 11279209
2016 Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene 127 27694895
2004 Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. The Journal of biological chemistry 118 15623513
2019 HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene 101 31375747
2008 High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Annals of surgical oncology 91 18506539
2007 Histone deacetylase inhibitors selectively suppress expression of HDAC7. Molecular cancer therapeutics 89 17876049
2014 MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer letters 86 25173798
2008 VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis. Arteriosclerosis, thrombosis, and vascular biology 81 18617643
2011 HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. The Journal of biological chemistry 77 21324898
2007 Myosin phosphatase dephosphorylates HDAC7, controls its nucleocytoplasmic shuttling, and inhibits apoptosis in thymocytes. Genes & development 73 17369396
2010 Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. The Journal of biological chemistry 72 21118817
2009 Splicing of HDAC7 modulates the SRF-myocardin complex during stem-cell differentiation towards smooth muscle cells. Journal of cell science 69 19174469
2009 Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. Modern rheumatology 66 19784544
2016 HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells. Diabetologia 63 27796421
2004 Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis. The Journal of biological chemistry 62 15364908
2022 HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway. Journal of experimental & clinical cancer research : CR 58 35277183
2009 Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PloS one 58 19484127
2017 Hdac7 promotes lung tumorigenesis by inhibiting Stat3 activation. Molecular cancer 57 29126425
2010 The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. Journal of molecular medicine (Berlin, Germany) 56 21120446
2013 HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLoS genetics 55 23696748
2019 A collagen hydrogel loaded with HDAC7-derived peptide promotes the regeneration of infarcted myocardium with functional improvement in a rodent model. Acta biomaterialia 54 30660010
2001 Tip60 and HDAC7 interact with the endothelin receptor a and may be involved in downstream signaling. The Journal of biological chemistry 54 11262386
2015 The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma. Cell death & disease 49 25675295
2020 Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling. The Journal of clinical investigation 45 32106109
2008 Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 45 19074726
2014 Histone deacetylase 7 (Hdac7) suppresses chondrocyte proliferation and β-catenin activity during endochondral ossification. The Journal of biological chemistry 44 25389289
2012 The angiogenesis suppressor gene AKAP12 is under the epigenetic control of HDAC7 in endothelial cells. Angiogenesis 43 22584896
2016 In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development. The Journal of experimental medicine 41 27810920
2013 PP2A regulatory subunit Bα controls endothelial contractility and vessel lumen integrity via regulation of HDAC7. The EMBO journal 40 23955003
2012 HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered β-catenin switch. Molecular endocrinology (Baltimore, Md.) 40 23204328
2022 Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability. Military Medical Research 39 36163081
2019 ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway. Journal of experimental & clinical cancer research : CR 36 30691485
2019 HDAC7-mediated control of tumour microenvironment maintains proliferative and stemness competence of human mammary epithelial cells. Molecular oncology 35 31081251
2010 Sp1-dependent activation of HDAC7 is required for platelet-derived growth factor-BB-induced smooth muscle cell differentiation from stem cells. The Journal of biological chemistry 35 20889501
2017 Tonic LAT-HDAC7 Signals Sustain Nur77 and Irf4 Expression to Tune Naive CD4 T Cells. Cell reports 34 28538176
2017 MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 34 29071516
2006 Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion. Experimental cell research 33 16860317
2018 MC1568 improves insulin secretion in islets from type 2 diabetes patients and rescues β-cell dysfunction caused by Hdac7 upregulation. Acta diabetologica 32 30088095
2016 HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies. Oncogene 32 26853466
2022 HDAC7 Activates IKK/NF-κB Signaling to Regulate Astrocyte-Mediated Inflammation. Molecular neurobiology 31 35871708
2020 HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis. Cell death & disease 30 32376822
2016 Pioglitazone up-regulates long non-coding RNA MEG3 to protect endothelial progenitor cells via increasing HDAC7 expression in metabolic syndrome. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 30 26898430
2020 MiR-489 inhibited the development of gastric cancer via regulating HDAC7 and PI3K/AKT pathway. World journal of surgical oncology 28 32284070
2017 HDAC7 Ubiquitination by the E3 Ligase CBX4 Is Involved in Contextual Fear Conditioning Memory Formation. The Journal of neuroscience : the official journal of the Society for Neuroscience 28 28283560
2013 VEGF-PKD1-HDAC7 signaling promotes endothelial progenitor cell migration and tube formation. Microvascular research 28 24189120
2024 PROTAC-Mediated HDAC7 Protein Degradation Unveils Its Deacetylase-Independent Proinflammatory Function in Macrophages. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 27 39049738
2021 The TGF-β/HDAC7 axis suppresses TCA cycle metabolism in renal cancer. JCI insight 26 34609963
2013 Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. Toxicology letters 25 24200999
2011 Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis. Molecular cancer 25 21314984
2022 WNT5A promotes the metastasis of esophageal squamous cell carcinoma by activating the HDAC7/SNAIL signaling pathway. Cell death & disease 24 35595735
2020 OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p. Oncology letters 24 32774481
2021 HDAC7 Inhibition by Phenacetyl and Phenylbenzoyl Hydroxamates. Journal of medicinal chemistry 23 33570940
2023 HDAC7 is an immunometabolic switch triaging danger signals for engagement of antimicrobial versus inflammatory responses in macrophages. Proceedings of the National Academy of Sciences of the United States of America 20 36649417
2025 Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis. Molecular neurodegeneration 19 39806423
2024 HDAC7 drives glioblastoma to a mesenchymal-like state via LGALS3-mediated crosstalk between cancer cells and macrophages. Theranostics 19 39629136
2022 KLF2 up-regulates IRF4/HDAC7 to protect neonatal rats from hypoxic-ischemic brain damage. Cell death discovery 19 35091544
2021 The histone deacetylase Hdac7 supports LPS-inducible glycolysis and Il-1β production in murine macrophages via distinct mechanisms. Journal of leukocyte biology 18 34811804
2024 HDAC7: a promising target in cancer. Frontiers in oncology 16 38487728
2022 Evidence that HDAC7 acts as an epigenetic "reader" of AR acetylation through NCoR-HDAC3 dissociation. Cell chemical biology 16 35709754
2022 A multiple sclerosis-protective coding variant reveals an essential role for HDAC7 in regulatory T cells. Science translational medicine 16 36516268
2024 Class IIa HDAC4 and HDAC7 cooperatively regulate gene transcription in Th17 cell differentiation. Proceedings of the National Academy of Sciences of the United States of America 15 38657041
2024 Mesenchymal Stem Cell-Derived Extracellular Vesicles Alleviate Brain Damage Following Subarachnoid Hemorrhage via the Interaction of miR-140-5p and HDAC7. Molecular neurobiology 14 38592585
2022 MiR-466b-3p/HDAC7 meditates transgenerational inheritance of testicular testosterone synthesis inhibition induced by prenatal dexamethasone exposure. Biochemical pharmacology 14 35351429
2022 MicroRNAs Promote the Progression of Sepsis-Induced Cardiomyopathy and Neurovascular Dysfunction Through Upregulation of NF-kappaB Signaling Pathway-Associated HDAC7/ACTN4. Frontiers in neurology 14 35756932
2010 Histone deacetylase 7 (HDAC7) regulates myocyte migration and differentiation. Biochimica et biophysica acta 14 20621129
2004 HDAC7 regulates apoptosis in developing thymocytes. Novartis Foundation symposium 14 15171250
2023 HDAC7/c-Myc signaling pathway promotes the proliferation and metastasis of choroidal melanoma cells. Cell death & disease 13 36653340
2022 HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer. Oncology letters 13 36589669
2021 MiR-342-3p inhibits LCSC oncogenicity and cell stemness through HDAC7/PTEN axis. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 12 34842937
2025 Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11 39887933
2020 A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1- pre-B-ALL. Cell death & disease 11 32913188
2024 Melatonin Attenuates Diabetic Retinopathy by Regulating EndMT of Retinal Vascular Endothelial Cells via Inhibiting the HDAC7/FOXO1/ZEB1 Axis. Journal of pineal research 10 39300782
2022 The HDAC7-TET2 epigenetic axis is essential during early B lymphocyte development. Nucleic acids research 10 35904805
2015 HDAC7 modulates TNF-α-mediated suppression of Leydig cell steroidogenesis. Molecular and cellular biochemistry 10 25916381
2025 Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function. Acta pharmaceutica Sinica. B 9 40370550
2023 LncRNA HOXB-AS4 promotes proliferation and migration of colorectal cancer via the miR-140-5p/hdac7 axis. Biotechnology & genetic engineering reviews 9 36951606
2020 HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients. Oncogene 9 32709923
2017 Bisphenol A deteriorates egg quality through HDAC7 suppression. Oncotarget 9 29190921
2013 Holocarboxylase synthetase acts as a biotin-independent transcriptional repressor interacting with HDAC1, HDAC2 and HDAC7. Molecular genetics and metabolism 9 24239178
2023 Deacetylation of FOXP1 by HDAC7 potentiates self-renewal of mesenchymal stem cells. Stem cell research & therapy 8 37507770
2014 Rho-kinase signaling controls nucleocytoplasmic shuttling of class IIa histone deacetylase (HDAC7) and transcriptional activation of orphan nuclear receptor NR4A1. Biochemical and biophysical research communications 8 25511694
2025 DNMT3a promotes LUAD cell proliferation and metastasis by activating the HDAC7 signalling pathway. International journal of biological sciences 7 39990668
2025 ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway. Hepatology communications 6 40536557
2024 HDAC7 promotes ovarian cancer malignancy via AKT/mTOR signalling pathway. Journal of cellular and molecular medicine 6 39431349
2024 Toxin protein LukS-PV targeting complement receptor C5aR1 inhibits cell proliferation in hepatocellular carcinoma via the HDAC7-Wnt/β-catenin axis. The Journal of biological chemistry 6 39736396
2020 The black sheep of class IIa: HDAC7 SIKens the heart. The Journal of clinical investigation 6 32364532
2024 Characterization of molecular interactions between HDAC7 and MEF2A. Journal of biomolecular structure & dynamics 5 39660765
2020 Transcription Factor ZNF326 Upregulates the Expression of ERCC1 and HDAC7 and its Clinicopathologic Significance in Glioma. Laboratory medicine 5 31930344
2010 Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate. Human gene therapy 5 20102258
2025 HDAC7 promotes renal cancer progression by reprogramming branched-chain amino acid metabolism. Science advances 4 40465706
2024 The Epigenetic Modifiers HDAC2 and HDAC7 Inversely Associate with Cancer Stemness and Immunity in Solid Tumors. International journal of molecular sciences 4 39063083
2024 HDAC7 is a potential therapeutic target in acute erythroid leukemia. Leukemia 4 39277669
2021 FBXW7 induces apoptosis in glioblastoma cells by regulating HDAC7. Cell biology international 4 34288252
2020 Correction to: ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway. Journal of experimental & clinical cancer research : CR 3 31941535
2016 Analysis of Histone Deacetylase 7 (HDAC7) Alternative Splicing and Its Role in Embryonic Stem Cell Differentiation Toward Smooth Muscle Lineage. Methods in molecular biology (Clifton, N.J.) 3 27246210
2025 Scaffolding Activities of Pseudodeacetylase HDAC7. ACS chemical biology 2 39908122
2025 Upregulated astrocytic HDAC7 induces depression-like disorders via deacetylating PINK1 and inhibiting mitophagy. Journal of neuroinflammation 2 41286926

Missed literature

Know a paper Affinage missed for HDAC7? Flag it for the maintainers and the community.

No submissions yet.